Loading…
Loading…
SPRC does not currently pay a dividend.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for SPRC and 80,000+ other tickers.
See exactly how SPRC's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for SPRC and 80,000+ other tickers.
SciSparc Ltd. is a pharmaceutical company in the clinical development phase, specializing in creating medications derived from cannabinoid molecules. Their therapeutic pipeline encompasses several key drug candidates: SCI-110, which is being investigated for the treatment of Tourette syndrome, obstructive sleep apnea, and agitation associated with Alzheimer's disease; SCI-160, designed to address pain; and SCI-210, targeting autism spectrum disorder and epilepsy. The company has formed strategic alliances to further its goals. A partnership with Procaps focuses on the development and eventual…
The addition of leading AI researcher further strengthens SciSparc's scientific and technical foundation as the Company advances its strategic focus on the Agentic AI market
U.S. publication of a patent application covering the MDMA-N-acylethanolamines combination expands intellectual property generated through the collaboration, and provides guidance addressing clinical development considerations for psychedelic drugs, including MDMA
SciSparc Invests C$2.7 million and holds approximately 44.6% of NeuroThera's issued and outstanding common shares following the financing
T oronto, Ontario – TheNewswire - August 17, 2026 – NeuroThera Labs Inc. (the “ Company ” or “ NeuroThera ”) (TSXV: NTLX), a clinical-stage biotech company and a majority-owned subsidiary of SciSparc Ltd. (Nasdaq: SPRC), is pleased to announce that it has closed the final tranche (the “ Final Tranche ”) of its non-brokered private placement (the “ Offering ”), as previously announced on June 30, 2026, July 2, 2026 and August 12, 2026. Under the Final Tranche, the Company raised C$2,700,000 from the sale of 22,500,000 units (each, a “ Unit ”) at C$0.12 per Unit. Each Unit is comprised of one common share in the capital of the Company (each, a “ Common Share ”) and one Common Share purchase warrant (each, a “ Unit Warrant ”). Each Unit Warrant entitles the holder to purchase one Common Share at an exercise price of US$0.115 per Common Share, equivalent to C$0.16 per Common Share, until August 17, 2029. The Unit Warrants are also subject to an acceleration provision whereby, upon the securities of NeuroThera being approved for trading on the Nasdaq Stock Market, the Company will accelerate the expiry date of 50% of the unexercised Unit Warrants and provide three business days' advance written notice to holders thereof of such accelerated expiry date. The Unit Warrants are non-transferable.
Toronto, Ontario – August 12, 2026 – TheNewswire - NeuroThera Labs Inc. (the “ Company ” or “ NeuroThera ”) (TSXV: NTLX), a clinical-stage biotech company and a majority-owned subsidiary of SciSparc Ltd. (Nasdaq: SPRC), is pleased to announce that it has closed the first tranche (the “ First Tranche ”) of its non-brokered private placement (the “ Offering ”), as previously announced on June 30, 2026 and July 2, 2026. Under the First Tranche, the Company raised C$2,700,000 from the sale of 22,500,000 units (each, a “ Unit ”) at C$0.12 per Unit. Each Unit is comprised of one common share in the capital of the Company (each, a “ Common Share ”) and one Common Share purchase warrant (each, a “ Unit Warrant ”). Each Unit Warrant entitles the holder to purchase one Common Share for US$0.115 per Common Share, equivalent to C$0.16 per Common Share, until August 1 2 , 2029. The Unit Warrants will also have an acceleration provision whereby upon the securities of NeuroThera being approved for trading on the Nasdaq Stock Market, the Company will accelerate the expiry date of 50% of the unexercised Unit Warrants and provide three (3) business days' advance written notice to holders thereof of such accelerated expiry date. The Unit Warrants are non-transferable.